Treatment of concomitant diseases and complications caused by impaired detoxification of the liver (for example, liver cirrhosis) with symptoms of latent or severe hepatic encephalopathy, especially disorders of consciousness (precoma, coma).
active substance: L-ornithine-L-aspartate;
1 ml of the drug contains L-ornithine-L-aspartate 500 mg
excipients: sodium edetate, sodium hydroxide, water for injection.
Concentrate for preparation of solution for infusion.
The in vivo action of L-ornithine-L-aspartate is mediated by the amino acids ornithine and aspartate, which detoxify ammonia through urea synthesis and glutamine synthesis.
Synthesis of urea occurs in navkoloportalny hepatocytes, where ornithine acts as an activator of two enzymes: ornithine carbamoyl transferase and carbamoyl phosphate synthetase, as well as a substrate for urea synthesis.
Glutamine synthesis occurs in the peri-venous hepatocytes. In particular, under pathological conditions, aspartate and dicarboxylate, including the metabolic products of ornithine, are absorbed into cells and used there to bind ammonia in the form of glutamine.
Glutamate is an amino acid that binds ammonia under both physiological and pathological conditions. The resulting amino acid – glutamine – is not only a non-toxic form for excreting ammonia, but also activates an important urea cycle (intracellular glutamine metabolism).
Under physiological conditions, ornithine and aspartate do not limit the synthesis of urea.
Experimental studies on animals have shown that the property of L-ornithine-L-aspartate to reduce the level of ammonia is due to the accelerated synthesis of glutamine. Separate clinical studies have shown this improvement relative to branched chain amino acids / aromatic amino acids.
Treatment of concomitant diseases and complications caused by impaired liver detoxification function (for example, in liver cirrhosis) with symptoms of latent or severe hepatic encephalopathy, especially impaired consciousness (coma, coma).
Hypersensitivity to L-ornithine-L-aspartate or other components of the drug.
Severe renal failure (creatinine clearance of 3 mg / 100 ml is considered a guideline value).
The experience of use in children is limited, so the drug is not used in pediatric practice.
Application during pregnancy or lactation
There are no data on the use of L-ornithine-L-aspartate during pregnancy, therefore, the use of Ornilivu during this period should be avoided. However, if treatment with Orniliv is considered necessary for health reasons, the doctor should carefully weigh the ratio of risk to the fetus / child and the expected benefit to the mother.
It is not known whether L-ornithine-L-aspartate passes into breast milk. So, you should avoid using the drug during breastfeeding.
Method of administration and dosage
Orniliv should be administered intravenously.
Unless otherwise prescribed, you can use up to 4 ampoules (40 ml) per day.
In the case of precoma or coma, up to 8 ampoules (80 ml) are injected within 24 hours, depending on the severity of the condition.
Before administration, the contents of the ampoules are added to 500 ml of solution, but more than 6 ampoules in 500 ml of solution should not be dissolved.
The maximum injection rate of the drug is 5 g / h (which corresponds to the content of 1 ampoule).
The course of treatment is regulated by the patient’s clinical condition.
So far, there have been no signs of intoxication due to an overdose of L-ornithine-L-aspartate. Possible increased side effects. In case of overdose, symptomatic treatment is recommended.
Allergic reactions are possible.
Store in its original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.